Sensitivity Analysis in Health Economic and Pharmacoeconomic Studies
- 230 Downloads
The objective of this study was to analyse the extent of reporting of sensitivity analyses in the health economics. medical and pharmacy literature between journal types and over time.
90 articles were chosen from each of the bodies of literature on health economics. medicine and pharmacy. MEDLINE. EMBASE and International Pharmaceutical Abstracts were searched for English-language economic studies published between 1989 and 1993.
The studies chosen for inclusion had to be original articles published in one of the selected journals between January 1989 and December 1993, involving a comparison between drugs, treatments or services. and evaluating both costs and outcomes. 123 articles initially met these criteria; however. 16 were inappropriate. 17 were randomised out. leaving 90 studies (73%) that were used (30 from each literature group). Data were extracted independently by 5 raters using a validated checklist. Inter-rater reliability was assessed by calculating K.
53 of the 90 articles (59%) conducted sensitivity analyses. 39 (74o/c) stated explicitly that a sensitivity analysis was being performed; this was noted in the Methods section of 35 papers (67%).80% of health economics journals. 70% of medical journals and 20% of pharmacy journals conducted sensitivity analyses.
Despite the fact that all published pharmacoeconomic guidelines suggest the use of sensitivity analysis. only 59% of studies between 1989 and 1993 did so. Improvement is required. especially in the pharmacy literature. No time trends in the conduct of sensitivity analyses were detected. However. the sample may not have been sufficient to detect such trends. Pharmacoeconomic guidelines should provide more details on preferred methods of sensitivity analysis and on desired parameters.
- 1.Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Toronto: Oxford Medical Publications, 1987Google Scholar
- 2.Glossary of terms used in health economics and pharmacoeconomic and quality-of-life analyses. PharmacoEconomics 1994; 6: 401–4Google Scholar
- 4.Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994Google Scholar
- 5.Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. 1st ed. Ottawa: CCOHTA, 1994Google Scholar
- 6.Australia Commonwealth Depanment of Health Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Australia Commonwealth Department of Health Housing and Community Services 1992Google Scholar
- 7.Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: a report on principles. Ann Intern Med 1995; 122: 61–70Google Scholar
- 11.McGhan WF, Lewis NJW. Issues in health policy: guidelines for pharmaeoeconomic studies. Clin Ther 1994; 14: 486–94Google Scholar
- 20.Division of Drug Marketing Advertising and Communications (DDMAC). Principles for the review of pharmacoeconomic promotion — draft. USA: 1995Google Scholar
- 22.Einarson T, Shear N, Oh P. Models for pharmacoeconomic analysis. Can J Clin Pharmacol. In pressGoogle Scholar